Key result
SGLT2i improves outcomes in patients with HFpEF and CKD.
Why the study?
There is a need to translate knowledge of cardiac imaging abnormalities in CKD to clinical outcomes such as heart failure admission and premature cardiovascular death, especially regarding HFpEF.
Population
Patients with CKD and HFpEF
Design
Review
Authors
Loading...
May support SGLT2 inhibitor consideration in HFpEF-CKD; leaves open confirmation in dedicated RCTs.
This review highlights the bidirectional relationship between CKD and HFpEF and discusses the emerging role of SGLT2 inhibitors in managing both conditions.
Mark et al. (2022) conducted a review in Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). Sodium-glucose cotransporter 2 (SGLT2) inhibitors was evaluated. Sodium-glucose cotransporter 2 inhibition offers a novel evidence-based therapy that improves outcomes in patients with heart failure with preserved ejection fraction and chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: